As shown in Table 5, currently available IL-4-, IL-5-, and IL-13-targeted therapies underscore the translational gap between the established indication in allergic diseases and the lack of clinical evidence in obesity. Here, IL4 is linked to obesity due to melanocortin 4 receptor deficiency.